Press

Optimi Health Granted Amendment to Dealer’s Licence by Health Canada to Supply Special Access Program

Sep 7 • 2 min read

Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a Canadian psychedelics drug research and formulation company, proudly announced today that Health Canada has approved an amendment to the Company’s Dealer’s Licence. The amendment empowers Optimi to embark on the formal supply journey for Canada’s Special Access Program (SAP), operating within the provisions of the…

Atai Life Sciences to Participate in Upcoming September Investor Conferences

Sep 6 • 2 min read

Atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in upcoming September Investor Conferences. Details of the company’s participation are as follows: Citi’s 18th Annual BioPharma Conference Format: 1×1 Only Date: Thursday, September 7th Location: Boston, MA H.C. Wainwright 25th Annual Global Investment Conference…

Awakn Life Sciences Submits Clinical Trial Application for Phase III Trial Of AWKN-P001

Sep 6 • 7 min read

AWAKN-P001 Is a N-methyl-D-aspartate Receptor-Modulating Drug Used in Combination with Psycho-Social Support for The Treatment of Severe Alcohol Use Disorder Awakn Life Sciences Corp. (NEO: AWKN, OTCQB: AWKNF, FSE: 954) (“Awakn”), a biotechnology company developing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), announces today it has submitted the Clinical Trial…

Clearmind Medicine Announces Clinical Research Collaboration with Johns Hopkins University to Evaluate CMND-100 in Patients with Alcohol Use Disorder

Sep 6 • 3 min read

Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the “company”), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, is pleased to announce that the company has entered into a Clinical Trial Agreement with Johns Hopkins University School of Medicine (“JHU”) to conduct its…

PharmAla Begins Trading on OTCQB

Sep 6 • 3 min read

PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTCQB:PMBHF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including MDMA), is pleased to announce that it has qualified for trading on the OTCQB Venture Market (the “OTCQB”) in the United States operated by the OTC Markets Group…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435